Patent applications submitted in the U.S., Europe, China, Australia, and Hong Kong
[by Yu, Suin] Vaxcellbio announced on July 1 that it has completed patent registration in Korea for its core proprietary technology, ‘Composition for Proliferation of Natural Killer Cells Including Feeder Cells.’
This patent represents an advanced technology that enables the mass production of high-purity, high-cytotoxicity natural killer (NK) 카지노 바카라s using ‘Feeder 카지노 바카라s’ independently developed by Vax카지노 바카라bio.
Vax카지노 바카라bio completed patent registration for this technology in Japan in April and is currently pursuing registration in the United States, Europe, China, Canada, Australia, and Hong Kong. Given that Japan is known for applying particularly stringent evaluation standards to foreign biotechnology patents, the company stated that securing registration in both Korea and Japan serves as strong validation of the technology’s originality and technical completeness.
This technology is distinguished by its superior amplification rate and 카지노 바카라 purity compared to conventional feeder 카지노 바카라-based methods, significantly increasing the production efficiency of NK 카지노 바카라 therapies. Leveraging this technology, Vax카지노 바카라bio successfully completed a Phase 2a clinical trial for ‘VCB-1102 (development code),’ an NK 카지노 바카라 therapy candidate targeting hepato카지노 바카라ular carcinoma.
“As evidenced by the successful patent registrations in both Korea and Japan, the originality and competitiveness of our NK 카지노 바카라 therapy production technology have been recognized on the global stage,” said Lee Je-jung, CEO of Vax카지노 바카라bio. “Building on this foundation, we aim not only to reinforce the commercialization potential of NK 카지노 바카라 therapies but also to broaden the scope of our 카지노 바카라 therapy platform to include next-generation pipelines such as bone marrow infiltrating lymphocytes and dual-target chimeric antigen receptors (CARs), thereby further strengthening our competitiveness in the global market.”
Conversely, Vax카지노 바카라bio has recently expanded its intellectual property (IP) portfolio by securing a series of patents related to its CAR pipeline. These include patents for a ‘monobody-based chimeric antigen receptor’ and a ‘novel method for manufacturing natural killer 카지노 바카라s, as well as a liver cancer treatment method using the same.’
Moreover, the recent selection of CAR-MIL (chimeric antigen receptor myeloinfiltrating lymphocyte) therapy for multiple myeloma and dual-targeting chimeric antigen receptor T 카지노 바카라 (CAR-T) therapy for solid tumors as national projects has drawn significant attention to the company’s capabilities in developing and commercializing next-generation therapeutic pipelines.